肝癌治療薬の世界市場：画期的医薬品の市場機会及び商用化...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 4
2.1 Unmet Needs and Limited Market Drive an Innovative Pipeline 4
2.2 Targeted Therapies Segment to Expand over the Coming Decade 4
2.3 Active Deals Landscape Reflects the Dynamic Pipeline 4
3 The Case for Innovation 5
3.1 Growing Opportunities for Biologic Products 6
3.2 Diversification of Molecular Targets 6
3.3 Innovative First-in-class Product Developments Remain Attractive 6
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7
3.5 Sustained Innovation 7
3.6 GBI Research Report Guidance 8
4 Clinical and Commercial Landscape 9
4.1 Disease Overview 9
4.2 Symptoms 9
4.3 Epidemiology and Etiology 9
4.4 Pathophysiology 10
4.4.1 Hepatocellular Carcinoma 11
4.4.2 Cholangiocarcinoma 13
4.4.3 Conclusion 14
4.5 Diagnosis 14
4.5.1 Clinical Presentation 14
4.5.2 Alpha-Fetoprotein 14
4.5.3 Diagnostic Imaging and Scans 14
4.5.4 Screening 15
4.5.5 Biopsy 15
4.5.6 Classification 15
4.6 Treatment Options 15
4.7 Treatment Algorithm 15
4.7.1 First Line 16
4.8 Overview of Marketed Products for Liver Cancer 17
4.8.1 Molecular Type and Target Analysis 17
4.8.2 Innovative Products in the Liver Cancer Market 18
4.8.3 Unmet Needs 19
5 Assessment of Pipeline Product Innovation 20
5.1 Liver Cancer Pipeline by Molecule Type, Phase and Therapeutic Target 20
5.2 Comparative Distribution of Programs between the Liver Cancer Market and Pipeline by Therapeutic Target Family 24
5.3 First-in-Class Pipeline Programs Targeting Novel Molecular Targets 25
6 Liver Cancer Patent Family Analysis 29
7 Signaling Network, Disease Causation and Innovation Alignment 37
7.1 The Complexity of Signaling Networks in Oncology 37
7.2 Signaling Pathways Disease-Causing Mutations and First-in-Class Molecular Target Integration 38
7.3 First-in-Class Target Matrix Assessment 41
8 First-in-Class Target Evaluation 47
8.1 Pipeline Programs Targeting β-Catenin 47
8.2 Pipeline Programs Targeting FGFR4 49
8.3 Pipeline Programs Targeting GPR55 50
8.4 Pipeline Programs Targeting Protein Disulfide Isomerase 52
8.5 Pipeline Programs Targeting Telomerase 53
8.6 Pipeline Programs Targeting Delta-Like 1 Homolog 55
8.7 Pipeline Programs Targeting eIF5A 56
8.8 Pipeline Programs Targeting FAK 58
8.9 Pipeline Programs Targeting TGFβ Receptor 60
8.10 Conclusion 62
9 Deals and Strategic Consolidations 63
9.1 Industry-wide First-in-Class Deals 63
9.2 Liver Cancer Deals Landscape 65
9.3 Licensing Deals 65
9.3.1 Molecule Types 68
9.3.2 Mechanism of Action 69
9.4 Co-Development Deals 70
9.4.1 Molecule Types 72
9.4.2 Mechanism of Action 73
9.5 First-In-Class Programs Not Involved in Licensing or Co-Development Deals 73
10 Appendix 76
10.1 References 76
10.2 Abbreviations 78
10.3 Contact Us 79
10.4 Disclaimer 79